Cancer prevention | Cancer treatment info » ovarian cancer

News From The American Journal Of Pathology, November 2009

truthseeker — Fri, 23 Oct 2009 10:21:23 +0000

A group led by Dr. Dieter BrÃ¶mme at the University of British Columbia has demonstrated that glycosaminoglycans (GAGs) contribute to skeletal abnormalities in patients with lysosomal storage diseases. Their report can be found in the November 2009 issue of The American Journal of Pathology. Mucopolysaccharidoses (MPS) are a group of diseases in which the dysfunction of a lysosomal enzyme results in decreased breakdown of GAGs, a type of carbohydrate, in various tissues.

Endocyte Presents Data On EC145 In Treatment Of Ovarian Cancer Before The European Society Of Gynaecologic Oncology

truthseeker — Fri, 23 Oct 2009 10:21:23 +0000

Officials of Endocyte Inc., a cancer drug discovery and development company, presented data from a Phase 2a clinical trial for EC145, currently in development as a potential treatment for advanced ovarian cancer. Results were presented at the European Society of Gynaecologic Oncology meeting in Belgrade, Serbia. In 49 women with advanced-stage ovarian cancer, EC145 was [...]

Metals Could Forge New Cancer Drug

truthseeker — Wed, 21 Oct 2009 10:21:01 +0000

Drugs made using unusual metals could form an effective treatment against colon and ovarian cancer, including cancerous cells that have developed immunity to other drugs, according to research at the University of Warwick and the University of Leeds.

Ovarian Cancer Patients Have Lower Death Risk When Treated By Experts

truthseeker — Mon, 19 Oct 2009 10:20:51 +0000

Women with ovarian cancer are less likely to die from their disease if they are treated by specialist gynaecological oncologists than if they are cared for by general gynaecologists, according to the results of a study carried out in Scotland, UK, and reported at this week’s 16th International Meeting of the European Society of Gynaecological [...]

CALYPSO Trial Shows New Chemotherapy Combination Prolongs Progression Free Survival In Ovarian Cancer

truthseeker — Mon, 19 Oct 2009 10:20:51 +0000

Treating women with relapsed platinum-sensitive ovarian cancer with combined carboplatin and pegylated liposomal doxorubicin prolongs progression free survival and is associated with a lower risk of severe, long lasting nerve damage than standard carboplatin/paclitaxel treatment.

European Patent Office To Issue Patent To Phyton Biotech Covering Methods Of Making Taxanes – Compounds Useful In Cancer Treatment

truthseeker — Thu, 15 Oct 2009 10:21:22 +0000

Phyton Biotech GmbH, a world leader in plant cell culture technology, reports that the European Patent Office has announced its intention to grant a European patent to Phyton covering methods of producing taxanes such as paclitaxel. Paclitaxel, the active ingredient in Bristol-Myers Squibb’s TAXOL®, is useful in the treatment of breast, ovarian, lung, [...]

Farletuzumab Data Presented On Phase II Clinical Trial In First-Relapsed Ovarian Cancer Subjects

truthseeker — Sat, 26 Sep 2009 10:20:51 +0000

Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, announced preliminary data from a Phase II trial evaluating the safety and efficacy of farletuzumab in platinum-sensitive epithelial ovarian cancer subjects experiencing their first relapse. Farletuzumab (MORAb-003) is a humanized monoclonal antibody that targets the Folate Receptor Alpha (FRA).

Gene Variant Shows Strong Gender Bias For Cancer Predisposition

truthseeker — Thu, 24 Sep 2009 10:21:00 +0000

Cancer predisposition resulting from the presence of a specific gene variant shows a strong gender bias, researchers at the University of Cincinnati (UC) have demonstrated. In addition, the research indicates that the risk for development of cancer in individuals harboring the gene variant can be further increased as a result of environmental [...]

Dose-Dense Chemotherapy Improves Both Overall And Progression-Free Survival In Advanced Ovarian Cancer

truthseeker — Tue, 22 Sep 2009 10:20:58 +0000

Women given a more intensive ‘dose-dense’ regimen of chemotherapy survive longer and have a higher-rate of progression free survival, concludes an Article published Online First in an upcoming edition of The Lancet. The Article is written by Dr Noriyuki Katsumata, National Cancer Center Hospital, Tokyo, Japan, and colleagues. Paclitaxel and carboplatin given every [...]

New Drug That Targets Inherited Breast And Ovarian Cancers May Work Against Other Cancers, Study

truthseeker — Fri, 18 Sep 2009 10:21:01 +0000

A new study suggests that a new type of cancer drug called PARP inhibitors, including a new drug called olaparib that is currently showing promising results in trials as a targeted treatment for inherited forms of breast and ovarian cancer, may also be effective against other cancers.